Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Receivables (2023 - 2025)

Historic Receivables for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $11.7 million.

  • Beta Bionics' Receivables changed N/A to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year change of. This contributed to the annual value of $12.1 million for FY2024, which is 16951.49% up from last year.
  • Beta Bionics' Receivables amounted to $11.7 million in Q3 2025.
  • Beta Bionics' Receivables' 5-year high stood at $12.1 million during Q4 2024, with a 5-year trough of $4.5 million in Q4 2023.
  • For the 3-year period, Beta Bionics' Receivables averaged around $9.8 million, with its median value being $11.5 million (2025).
  • Over the last 5 years, Beta Bionics' Receivables had its largest YoY gain of 16951.49% in 2024, and its largest YoY loss of 16951.49% in 2024.
  • Beta Bionics' Receivables (Quarter) stood at $4.5 million in 2023, then soared by 169.51% to $12.1 million in 2024, then fell by 3.57% to $11.7 million in 2025.
  • Its Receivables stands at $11.7 million for Q3 2025, versus $11.5 million for Q2 2025 and $9.2 million for Q1 2025.